title: Prevalence, susceptibility profile and proteinase production of yeasts causing vulvovaginitis in Turkish women.
abstract: In this study the prevalence of vulvovaginal candidiasis (VVC), antifungal susceptibility and proteinase production of isolated Candida species were investigated. Vaginal swabs were collected from symptomatic women with vulvovaginitis attending the Obstetrics and Gynecology Clinic of Kocaeli University, Turkey. The relation between risk factors, such as pregnancy, diabetes mellitus, antibiotic and corticosteroid use, history of sexually transmitted diseases and contraceptive methods, was recorded. Candida spp. were identified by conventional methods, then evaluated for proteinase secretion in a medium containing casein. Antifungal susceptibility was determined according to the NCCLS microdilution method. The prevalence of women with vulvovaginitis was 35.7% (170/6080) and 16% (28/170) of them were diagnosed as VVC. Candida albicans was the dominant species: 21 (75%), followed by 4 C. glabrata (14%), 2 C. tropicalis (7%), and one C. krusei (3.5%). All isolates were susceptible to fluconazole, itraconazole and amphotericin B, except one C. krusei, one C. glabrata and one C. albicans that were resistant to fluconazole. Proteinase production was determined in 19 (90.5%) C. albicans and in all C. tropicalis isolates. Proteinase activity was not associated with antifungal resistance. No association was found between risk factors and VVC.
authors.affiliation: Department of Microbiology, Medical Faculty, Kocaeli University, Kocaeli, Turkey.
authors.forename: Sema Keceli
authors.initials: SK
authors.lastname: Ozcan
authors.forename: Fatma
authors.initials: F
authors.lastname: Budak
authors.forename: Gulseren
authors.initials: G
authors.lastname: Yucesoy
authors.forename: Serdar
authors.initials: S
authors.lastname: Susever
authors.forename: Ayse
authors.initials: A
authors.lastname: Willke
mesh_terms: D000328:Adult; D000666:Amphotericin B / Q000494:pharmacology; D000935:Antifungal Agents / Q000494:pharmacology*; D002175:Candida / Q000187:drug effects* / Q000201:enzymology* / Q000302:isolation & purification / Q000378:metabolism; D002181:Candidiasis, Vulvovaginal / Q000453:epidemiology / Q000382:microbiology*; D005260:Female; D015725:Fluconazole / Q000494:pharmacology; D006801:Humans; D017964:Itraconazole / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D010447:Peptide Hydrolases / Q000096:biosynthesis*; D015995:Prevalence; D012307:Risk Factors; D014421:Turkey / Q000453:epidemiology
chemical_list: D000935:Antifungal Agents; D017964:Itraconazole; D000666:Amphotericin B; D015725:Fluconazole; D010447:Peptide Hydrolases